Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 10
1988 9
1989 14
1990 6
1991 7
1992 21
1993 13
1994 15
1995 10
1996 19
1997 14
1998 17
1999 9
2000 14
2001 12
2002 10
2003 15
2004 10
2005 10
2006 14
2007 15
2008 11
2009 15
2010 20
2011 25
2012 19
2013 27
2014 33
2015 37
2016 41
2017 40
2018 48
2019 58
2020 68
2021 53
Text availability
Article attribute
Article type
Publication date

Search Results

668 results
Results by year
Filters applied: . Clear all
Page 1
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.
Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB 3rd, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S. Dasari A, et al. Nat Rev Clin Oncol. 2020 Dec;17(12):757-770. doi: 10.1038/s41571-020-0392-0. Epub 2020 Jul 6. Nat Rev Clin Oncol. 2020. PMID: 32632268 Free PMC article. Review.
An increasing number of studies are describing potential uses of circulating tumour DNA (ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area of research, the Colon and Rectal-Anal Task Forces of the United States National …
An increasing number of studies are describing potential uses of circulating tumour DNA (ctDNA) in the care of patients with colorectal c
'Watch and wait' after chemoradiotherapy for rectal cancer.
Mullaney TG, Lightner AL, Johnston M, Keck J, Wattchow D. Mullaney TG, et al. ANZ J Surg. 2018 Sep;88(9):836-841. doi: 10.1111/ans.14352. Epub 2018 Jul 25. ANZ J Surg. 2018. PMID: 30047201 Review.
Surgery remains the cornerstone of rectal cancer treatment. However, there is significant morbidity and mortality associated with pelvic surgery, and the past decade has illustrated that a cohort of rectal cancer patients sustain a remission of local d …
Surgery remains the cornerstone of rectal cancer treatment. However, there is significant morbidity and mortality associated w …
Rising Proportion of Young Individuals With Rectal and Colon Cancer.
Kasi PM, Shahjehan F, Cochuyt JJ, Li Z, Colibaseanu DT, Merchea A. Kasi PM, et al. Clin Colorectal Cancer. 2019 Mar;18(1):e87-e95. doi: 10.1016/j.clcc.2018.10.002. Epub 2018 Oct 17. Clin Colorectal Cancer. 2019. PMID: 30420120 Free article.
We aimed to report the characteristics and trend of the rising proportion of young individuals being diagnosed with rectal and colon cancers at our institutions. PATIENTS AND METHODS: This study included 3381 rectal and colon cancer patients from the Mayo Cli …
We aimed to report the characteristics and trend of the rising proportion of young individuals being diagnosed with rectal and colon …
Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer: Follow-up Results of the ACOSOG Z6051 Randomized Controlled Trial.
Fleshman J, Branda ME, Sargent DJ, Boller AM, George VV, Abbas MA, Peters WR Jr, Maun DC, Chang GJ, Herline A, Fichera A, Mutch MG, Wexner SD, Whiteford MH, Marks J, Birnbaum E, Margolin DA, Larson DW, Marcello PW, Posner MC, Read TE, Monson JRT, Wren SM, Pisters PWT, Nelson H. Fleshman J, et al. Ann Surg. 2019 Apr;269(4):589-595. doi: 10.1097/SLA.0000000000003002. Ann Surg. 2019. PMID: 30080730 Free PMC article. Clinical Trial.
OBJECTIVE: To determine the disease-free survival (DFS) and recurrence after the treatment of patients with rectal cancer with open (OPEN) or laparoscopic (LAP) resection. BACKGROUND: This randomized clinical trial (ACOSOG [Alliance] Z6051), performed between 2008 a …
OBJECTIVE: To determine the disease-free survival (DFS) and recurrence after the treatment of patients with rectal cancer with …
Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance).
Schrag D, Weiser M, Saltz L, Mamon H, Gollub M, Basch E, Venook A, Shi Q. Schrag D, et al. Clin Trials. 2019 Apr;16(2):165-175. doi: 10.1177/1740774518824539. Epub 2019 Jan 28. Clin Trials. 2019. PMID: 30688523 Free PMC article. Clinical Trial.
BACKGROUND: More than half of the 40,000 incident rectal cancer patients in the United States each year are diagnosed at clinical stage II and III (locally advanced stage). ...METHODS: PROSPECT is an ongoing multi-site two-group seamless phase II/III randomized tria …
BACKGROUND: More than half of the 40,000 incident rectal cancer patients in the United States each year are diagnosed at clini …
Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes: The ACOSOG Z6051 Randomized Clinical Trial.
Fleshman J, Branda M, Sargent DJ, Boller AM, George V, Abbas M, Peters WR Jr, Maun D, Chang G, Herline A, Fichera A, Mutch M, Wexner S, Whiteford M, Marks J, Birnbaum E, Margolin D, Larson D, Marcello P, Posner M, Read T, Monson J, Wren SM, Pisters PW, Nelson H. Fleshman J, et al. JAMA. 2015 Oct 6;314(13):1346-55. doi: 10.1001/jama.2015.10529. JAMA. 2015. PMID: 26441179 Free PMC article. Clinical Trial.
IMPORTANCE: Evidence about the efficacy of laparoscopic resection of rectal cancer is incomplete, particularly for patients with more advanced-stage disease. ...CONCLUSIONS AND RELEVANCE: Among patients with stage II or III rectal cancer, the use of la …
IMPORTANCE: Evidence about the efficacy of laparoscopic resection of rectal cancer is incomplete, particularly for patients wi …
Radiation Therapy for Rectal Cancer: Executive Summary of an ASTRO Clinical Practice Guideline.
Wo JY, Anker CJ, Ashman JB, Bhadkamkar NA, Bradfield L, Chang DT, Dorth J, Garcia-Aguilar J, Goff D, Jacqmin D, Kelly P, Newman NB, Olsen J, Raldow AC, Ruiz-Garcia E, Stitzenberg KB, Thomas CR Jr, Wu QJ, Das P. Wo JY, et al. Pract Radiat Oncol. 2021 Jan-Feb;11(1):13-25. doi: 10.1016/j.prro.2020.08.004. Epub 2020 Oct 21. Pract Radiat Oncol. 2021. PMID: 33097436
PURPOSE: This guideline reviews the evidence and provides recommendations for the indications and appropriate technique and dose of neoadjuvant radiation therapy (RT) in the treatment of localized rectal cancer. METHODS: The American Society for Radiation Oncology c …
PURPOSE: This guideline reviews the evidence and provides recommendations for the indications and appropriate technique and dose of neoadjuv …
Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.
O'Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, Pitot HC, Shields AF, Landry JC, Ryan DP, Parda DS, Mohiuddin M, Arora A, Evans LS, Bahary N, Soori GS, Eakle J, Robertson JM, Moore DF Jr, Mullane MR, Marchello BT, Ward PJ, Wozniak TF, Roh MS, Yothers G, Wolmark N. O'Connell MJ, et al. J Clin Oncol. 2014 Jun 20;32(18):1927-34. doi: 10.1200/JCO.2013.53.7753. Epub 2014 May 5. J Clin Oncol. 2014. PMID: 24799484 Free PMC article. Clinical Trial.
PURPOSE: The optimal chemotherapy regimen administered concurrently with preoperative radiation therapy (RT) for patients with rectal cancer is unknown. National Surgical Adjuvant Breast and Bowel Project trial R-04 compared four chemotherapy regimens administered c …
PURPOSE: The optimal chemotherapy regimen administered concurrently with preoperative radiation therapy (RT) for patients with rectal
Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
Allegra CJ, Yothers G, O'Connell MJ, Beart RW, Wozniak TF, Pitot HC, Shields AF, Landry JC, Ryan DP, Arora A, Evans LS, Bahary N, Soori G, Eakle JF, Robertson JM, Moore DF Jr, Mullane MR, Marchello BT, Ward PJ, Sharif S, Roh MS, Wolmark N. Allegra CJ, et al. J Natl Cancer Inst. 2015 Sep 14;107(11):djv248. doi: 10.1093/jnci/djv248. Print 2015 Nov. J Natl Cancer Inst. 2015. PMID: 26374429 Free PMC article. Clinical Trial.
BACKGROUND: National Surgical Adjuvant Breast and Bowel Project R-04 was designed to determine whether the oral fluoropyrimidine capecitabine could be substituted for continuous infusion 5-FU in the curative setting of stage II/III rectal cancer during neoadjuvant r …
BACKGROUND: National Surgical Adjuvant Breast and Bowel Project R-04 was designed to determine whether the oral fluoropyrimidine capecitabin …
Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
Garcia-Aguilar J, Renfro LA, Chow OS, Shi Q, Carrero XW, Lynn PB, Thomas CR Jr, Chan E, Cataldo PA, Marcet JE, Medich DS, Johnson CS, Oommen SC, Wolff BG, Pigazzi A, McNevin SM, Pons RK, Bleday R. Garcia-Aguilar J, et al. Lancet Oncol. 2015 Nov;16(15):1537-1546. doi: 10.1016/S1470-2045(15)00215-6. Epub 2015 Oct 22. Lancet Oncol. 2015. PMID: 26474521 Free PMC article. Clinical Trial.
BACKGROUND: Local excision is an organ-preserving treatment alternative to transabdominal resection for patients with stage I rectal cancer. However, local excision alone is associated with a high risk of local recurrence and inferior survival compared with transabd …
BACKGROUND: Local excision is an organ-preserving treatment alternative to transabdominal resection for patients with stage I rectal
668 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page